BMY vs CNC: fair value comparison
Bristol-Myers Squibb Company and Centene Corporation · Updated 2026-10-19
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, BMY currently sits closer to the top of our ranking by discount to fair value. BMY carries the stronger quality grade.
| BMY | CNC | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $59.12 | $65.36 |
| 12-month range | $42.60–$68.09 | $31.80–$70.51 |
| Rank by discount to fair value | #72 of 108 Healthcare | #106 of 108 Healthcare |
| Quality grade | B | F |
| Leverage | High | Moderate |
| Margin trend | Expanding | Expanding |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Undervalued | — |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: BMY fair value analysis · CNC fair value analysis